Please use this identifier to cite or link to this item:
Title: Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor Malignancies.
Austin Authors: Sasadeusz, Joe;Grigg, Andrew P ;Hughes, Peter D;Lim, Seng Lee;Lucas, Michaela;McColl, Geoff;McLachlan, Sue Anne;Peters, Marion G;Shackel, Nicholas;Slavin, Monica;Sundararajan, Vijaya;Thompson, Alexander;Doyle, Joseph;Rickard, James;De Cruz, Peter P ;Gish, Robert G;Visvanathan, Kumar
Affiliation: University of Western Australia, 35 Stirling Highway, Crawley, Western Australia 6009, Australia
Victorian Comprehensive Cancer Centre, 305 Grattan Street, Melbourne, Victoria 3000, Australia
Department of Public Health, La Trobe University, Plenty Road, Bundoora, Victoria 3086, Australia
Burnet Institute, 85 Commercial Road, Melbourne, Victoria 3004, Australia
The Alfred and Monash University, 85 Commercial Road, Melbourne, Victoria 3004, Australia
St Vincent's Hospital, 41 Victoria Street, Fitzroy, Victoria 3065, Australia
Royal Melbourne Hospital, 300 Grattan Street, Parkville, Victoria 3050, Australia
University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia
Peter Doherty Institute for Infection and Immunity, Elizabeth Street, Melbourne, Victoria 3000, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Ingham Institute, 1 Campbell Street, Liverpool, Sydney, North South Wales 2170, Australia
University of Queensland Oral Health Centre, 288 Herston Road, Queensland 4006, Australia
National University of Singapore, 21 Lower Kent Ridge Road, Singapore 119077, Singapore
University of California, San Francisco, S357 Parnassus Avenue, San Francisco, CA 94143, USA
Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
Austin Health, Heidelberg, Victoria, Australia
Issue Date: Aug-2019 2019-06-06
Publication information: Clinics in liver disease 2019; 23(3): 511-519
Abstract: Patients with malignancies require chemotherapy and other immunosuppressive therapies for treatment. Because of this immunosuppression, in patients who have ever been exposed to hepatitis B it is possible for reactivation to occur. This reactivation can be fatal. Reactivation is particularly likely in patients who receive B cell-active agents such as rituximab. The occurrence of reactivation flares may also delay further chemotherapy, which can negatively affect the outcome of the underlying malignancy. Accordingly, it is important to screen patients for markers of hepatitis B and institute antiviral prophylaxis to prevent reactivation.
DOI: 10.1016/j.cld.2019.04.011
ORCID: 0000-0002-3399-7236
PubMed URL: 31266624
Type: Journal Article
Subjects: Cancer
Hematological malignancy
Hepatitis B
Solid tumors
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 2, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.